Skip to content
Shorla Oncology: A Leader in Innovative Oncology Solutions
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

News

Shorla Oncology

Shorla Oncology develops and commercializes innovative oncology drugs, where existing treatments are limited, in shortage or inadequate.

April 29th 2025November 26th 2024

Read More

Logo

Shorla Oncology Announces FDA Approval of IMKELDI (imatinib mesylate)

November 26th 2024November 26th 2024

Read More

Logo

Shorla Oncology Announces U.S. Food and Drug Administration (FDA) Expanded Approval of JYLAMVO™ (methotrexate), an Oncology and Autoimmune Drug for Pediatric Indications

November 21st 2024

Read More

Shorla Oncology

Shorla Oncology will be attending The (ACR) Convergence 2024 in Washington DC from Nov 14-19

November 13th 2024

Read More

Shorla Oncology

Shorla Oncology at ASHP Mid Year 2024, New Orleans, Dec 8-12

November 13th 2024November 11th 2024

Read More

Logo

Shorla, Protega Win Expanded Nods for Cancer/Autoimmune, Pain Therapies

November 8th 2024November 1st 2024

Read More

FDA

FDA expands Jylamvo approval to include polyarticular juvenile idiopathic arthritis, ALL

February 20th 2025November 1st 2024

Read More

PH

FDA Expands Methotrexate Indication to Included Children With Acute Lymphoblastic Leukemia

November 14th 2024November 1st 2024

Read More

ONC NEWS CENTRAL LOGO

FDA Expands Liquid Methotrexate Indication to Pediatric ALL Patients

April 29th 2025November 1st 2024

Read More

Older posts
Newer posts
Page1 … Page4 Page5 Page6 … Page19
Logo

IRELAND HQ:
Questum Acceleration Center,
Ballingarrane Science & Technology Park,
Clonmel, Co. Tipperary,
E91 V329, Ireland

Shorla Pharma Ltd trading as Shorla Oncology®

All trademarks are the property of their respective owners.

US OFFICE:
245 Main St.,
2nd floor,
Cambridge,
MA 02142, USA

SITEMAP

PRIVACY POLICY

CALIFORNIA COMPLIANCE PROGRAM DECLARATION

Company number: 618033
©SHORLA ONCOLOGY® 2025

© 2025 Shorla Oncology: A Leader in Innovative Oncology Solutions • Built with GeneratePress
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

Now approved for use in Pediatrics

  • Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA).
  • Treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.

Please click here for the full Prescribing information, including Boxed Warning regarding embryo-fetal toxicity, hypersensitivity reactions, and severe adverse reactions.